Kazia Therapeutics (ASX:KZA) ROCE % : -105.86% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Kazia Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kazia Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -105.86%.

Kazia Therapeutics ROCE % Historical Data

The historical data trend for Kazia Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics ROCE % Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-47.06

-70.62

-18.44

-63.26

-97.21

Kazia Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-61.04	-72.09	-106.09	-98.29	-105.86

Kazia Therapeutics ROCE % Calculation

Kazia Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-24.146	/	( ( (35.889 - 6.728)	+	(28.084 - 7.565) )	/ 2 )
	=	-24.146	/	( (29.161	+	20.519)	/ 2 )
	=	-24.146	/	24.84
	=	-97.21 %

Kazia Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-17.766	/	( ( (28.084 - 7.565)	+	(24.383 - 11.336) )	/ 2 )
	=	-17.766	/	( ( 20.519	+	13.047 )	/ 2 )
	=	-17.766	/	16.783
	=	-105.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Kazia Therapeutics (ASX:KZA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kazia Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (ASX:KZA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (ASX:KZA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KZIA:USA

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Kazia Therapeutics (ASX:KZA) Headlines

No Headlines